Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) covers the month of August 2004, specifically reporting on the expiration of its tender offers for Aventis. The filing announces that the French, German, and U.S. tender offers expired simultaneously on July 30, 2004. The document serves to inform investors of the preliminary tender results and the timeline for definitive results from the French Autorite des marches financiers (AMF).
Key Financial Metrics and Transaction Data
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. Instead, it focuses on transaction-specific data regarding the acquisition of Aventis:
- U.S. ADS Tenders: As of 5:00 p.m. EDT on July 30, 2004, a total of 25,131,998 Aventis ADSs were tendered and not withdrawn.
- Guaranteed Delivery: Included in the total were 1,741,137 Aventis ADSs subject to the guaranteed delivery period.
- Ownership Percentage: These tenders represented approximately 92.9% of Aventis ADSs outstanding and approximately 3.2% of Aventis share capital (as of July 29, 2004).
- Ordinary Shares: The number of Aventis ordinary shares tendered in France is not yet available due to centralization procedures.
Material Changes and Transaction Status
The primary material event is the conclusion of the tender period for the proposed acquisition of Aventis. Holders can no longer tender shares or withdraw previously tendered shares. The filing notes that the U.S. tender results are not final and must be combined with results from the French and German offers to determine the overall outcome. The definitive results are expected to be published by the AMF on August 12, 2004, with provisional results potentially announced earlier if the minimum tender condition is met.
Guidance, Outlook, and Risks
Outlook and Next Steps: Sanofi expects the AMF to publish definitive results on August 12, 2004. The company will issue press releases promptly following AMF announcements. Completion of the offers is subject to the same conditions across all three jurisdictions (France, Germany, U.S.).
Risks and Contingencies: The filing includes a standard forward-looking statements disclaimer. Key risks identified that could cause actual results to differ from projections include:
- The ability to expand profitably in the United States.
- The success of research and development programs.
- The ability to protect intellectual property rights.
- Risks associated with healthcare cost reimbursement and pricing reforms in the U.S. and Europe.
Regulatory Constraints: The document emphasizes that no offering of securities shall be made in the U.S. except via a prospectus meeting Section 10 requirements of the Securities Act of 1933. The solicitation of offers to buy Sanofi shares in the U.S. is restricted until the registration statement becomes effective.
Key Facts for Investor Verification
- Verify the definitive tender results published by the AMF on or after August 12, 2004, to confirm if the minimum tender condition was met.
- Review the Registration Statement on Form F-4 (File No. 333-112314) and related prospectus supplements for full terms of the revised offer.
- Monitor announcements regarding the combination of U.S., French, and German tender results to assess the total acquisition stake.
- Confirm the status of the registration statement effectiveness before any U.S. securities transactions occur.